The association of ESBL Escherichia coli with mortality in patients with Escherichia coli bacteremia at the emergency department
- PMID: 36304435
- PMCID: PMC9589459
- DOI: 10.33393/dti.2022.2422
The association of ESBL Escherichia coli with mortality in patients with Escherichia coli bacteremia at the emergency department
Abstract
Background:: Escherichia coli is a common bloodstream infection pathogen in the emergency department (ED). Patients with extended-spectrum beta-lactamase (ESBL) E. coli have a higher risk of morbidity. However, there is still debate surrounding ESBL E. coli-associated mortality in community, intensive care unit, and tertiary care settings. In addition, there have been few studies regarding mortality in ESBL E. coli in ED settings, and results have been contradictory.
Methods:: This was a retrospective cohort study conducted at the Department of Emergency Medicine, Faculty of Medicine, Khon Kaen University in Thailand aimed at evaluating the possible association between ESBL E. coli bacteremia and mortality in the ED. The inclusion criteria were age 18 years or over, clinical presentation suspicious of infection, and positive blood culture for E. coli. Predictors for mortality were analyzed by logistic regression analysis.
Results:: During the study period, 273 patients presented at the ED with hemoculture positive for E. coli. Of those, 27 (9.89%) died. Five factors remained in the final model, of which plasma glucose levels, serum lactate levels, and ESBL E. coli were significantly associated with 28-day mortality in the ED with adjusted odds ratios of 0.970, 1.258, and 12.885, respectively. Plasma glucose of less than 113 mg/dL yielded a sensitivity of 80.95% and specificity of 64.29%, while serum lactate over 2.4 mmol/L had a sensitivity of 81.48% and specificity of 45.50%.
Conclusion:: ESBL E. coli, plasma glucose, and serum lactate levels were associated with 28-day mortality in patients with E. coli bacteremia presenting at the ED.
Conflict of interest statement
Conflict of interest: The authors declare that they have no conflicts of interest.
Similar articles
-
Association between dementia and reduced walking ability and 30-day mortality in patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia.Eur J Clin Microbiol Infect Dis. 2017 Dec;36(12):2417-2422. doi: 10.1007/s10096-017-3077-6. Epub 2017 Aug 12. Eur J Clin Microbiol Infect Dis. 2017. PMID: 28801698
-
Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli.J Infect Chemother. 2018 Nov;24(11):944-947. doi: 10.1016/j.jiac.2018.04.016. Epub 2018 May 24. J Infect Chemother. 2018. PMID: 29803763
-
Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital.Intern Med. 2017;56(14):1807-1815. doi: 10.2169/internalmedicine.56.7702. Epub 2017 Jul 15. Intern Med. 2017. PMID: 28717075 Free PMC article.
-
Molecular epidemiology and clinical features of extended-spectrum beta-lactamase- or carbapenemase-producing Escherichia coli bacteremia in Japan.PLoS One. 2018 Aug 29;13(8):e0202276. doi: 10.1371/journal.pone.0202276. eCollection 2018. PLoS One. 2018. PMID: 30157275 Free PMC article.
-
Risk factors for 28-day mortality in elderly patients with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia.Arch Gerontol Geriatr. 2014 Jan-Feb;58(1):105-9. doi: 10.1016/j.archger.2013.07.002. Epub 2013 Aug 8. Arch Gerontol Geriatr. 2014. PMID: 23988261
Cited by
-
ESBL and carbapenemase-producing Enterobacteriaceae in infectious pleural effusions: current epidemiology at Hôpital du Mali.Drug Target Insights. 2023 Aug 29;17:92-100. doi: 10.33393/dti.2023.2613. eCollection 2023 Jan-Dec. Drug Target Insights. 2023. PMID: 37654725 Free PMC article.
-
One decade of point-prevalence surveys for carriage of extended-spectrum beta-lactamase-producing enterobacterales: whole genome sequencing based prevalence and genetic characterization in a large Dutch teaching hospital from 2013 to 2022.Antimicrob Resist Infect Control. 2024 Sep 12;13(1):102. doi: 10.1186/s13756-024-01460-y. Antimicrob Resist Infect Control. 2024. PMID: 39267161 Free PMC article.
References
-
- Sianipar O, Asmara W, Dwiprahasto I, Mulyono B. Mortality risk of bloodstream infection caused by either Escherichia coli or Klebsiella pneumoniae producing extended-spectrum β-lactamase: a prospective cohort study. BMC Res Notes. 2019;12(1):719. doi: 10.1186/s13104-019-4751-9. PubMed - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources